Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level.

Harismendy O, Bansal V, Bhatia G, Nakano M, Scott M, Wang X, Dib C, Turlotte E, Sipe JC, Murray SS, Deleuze JF, Bafna V, Topol EJ, Frazer KA.

Genome Biol. 2010;11(11):R118. doi: 10.1186/gb-2010-11-11-r118. Epub 2010 Nov 30.

2.

Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.

Sipe JC.

Expert Rev Neurother. 2010 Mar;10(3):365-75. doi: 10.1586/ern.10.12. Review.

PMID:
20187859
3.

Biomarkers of endocannabinoid system activation in severe obesity.

Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J.

PLoS One. 2010 Jan 20;5(1):e8792. doi: 10.1371/journal.pone.0008792.

4.

Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

Proudnikov D, Kroslak T, Sipe JC, Randesi M, Li D, Hamon S, Ho A, Ott J, Kreek MJ.

Pharmacogenomics J. 2010 Jun;10(3):232-42. doi: 10.1038/tpj.2009.59. Epub 2009 Dec 15.

5.

Cladribine tablets' potential in multiple: sclerosis treatment.

Costello K, Sipe JC.

J Neurosci Nurs. 2008 Oct;40(5):275-80. Review.

PMID:
18856248
6.

The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.

Tyndale RF, Payne JI, Gerber AL, Sipe JC.

Am J Med Genet B Neuropsychiatr Genet. 2007 Jul 5;144B(5):660-6.

PMID:
17290447
7.

The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction.

Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC.

Hum Genet. 2006 Nov;120(4):581-8. Epub 2006 Sep 14.

PMID:
16972078
8.

Cladribine for multiple sclerosis: review and current status.

Sipe JC.

Expert Rev Neurother. 2005 Nov;5(6):721-7. Review.

PMID:
16274330
9.

Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders.

Sipe JC, Arbour N, Gerber A, Beutler E.

J Leukoc Biol. 2005 Jul;78(1):231-8. Epub 2005 Apr 21.

PMID:
15845647
10.

Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).

Sipe JC, Waalen J, Gerber A, Beutler E.

Int J Obes (Lond). 2005 Jul;29(7):755-9.

PMID:
15809662
11.
12.

A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Arbour N, Holz A, Sipe JC, Naniche D, Romine JS, Zyroff J, Oldstone MB.

J Neuroimmunol. 2003 Apr;137(1-2):197-209.

13.

Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease.

Lee PL, Gelbart T, West C, Halloran C, Sipe JC, Beutler E.

Mov Disord. 2002 Nov;17(6):1302-4.

PMID:
12465072
14.

Brain iron metabolism and neurodegenerative disorders.

Sipe JC, Lee P, Beutler E.

Dev Neurosci. 2002;24(2-3):188-96. Review.

PMID:
12401958
15.

Dysregulation of protein modification by ISG15 results in brain cell injury.

Ritchie KJ, Malakhov MP, Hetherington CJ, Zhou L, Little MT, Malakhova OA, Sipe JC, Orkin SH, Zhang DE.

Genes Dev. 2002 Sep 1;16(17):2207-12.

16.

A missense mutation in human fatty acid amide hydrolase associated with problem drug use.

Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8394-9.

17.

Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.

Koziol JA, Wagner S, Sobel DF, Slivka LS, Romine JS, Sipe JC, Adams HP.

AJNR Am J Neuroradiol. 2001 Feb;22(2):284-91.

18.

New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.

Wagner S, Adams H, Sobel DF, Slivka LS, Sipe JC, Romine JS, Koziol JA.

Eur Neurol. 2000;43(4):194-200.

PMID:
10828648
19.

Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents.

Sipe JC, Filippi M, Martino G, Furlan R, Rocca MA, Rovaris M, Bergami A, Zyroff J, Scotti G, Comi G.

Magn Reson Imaging. 1999 Dec;17(10):1521-3.

PMID:
10610001
20.

Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial.

Koziol JA, Lucero A, Sipe JC, Romine JS, Beutler E.

Can J Neurol Sci. 1999 Nov;26(4):283-9.

PMID:
10563213
21.

Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.

Adams HP, Wagner S, Sobel DF, Slivka LS, Sipe JC, Romine JS, Beutler E, Koziol JA.

Eur Neurol. 1999 Jul;42(1):52-63.

PMID:
10394049
22.

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.

Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E.

Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):35-44.

PMID:
9893155
23.

Cladribine.

Romine JS, Sipe JC, Koziol JA, Zyroff J, McMillan R, Beutler E.

BioDrugs. 1997 May;7(5):386-93.

PMID:
18031102
24.

Development of cladribine treatment in multiple sclerosis.

Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E.

Mult Scler. 1996 Jul;1(6):343-7.

PMID:
9345414
25.

A comparison of two neurologic scoring instruments for multiple sclerosis.

Koziol JA, Frutos A, Sipe JC, Romine JS, Beutler E.

J Neurol. 1996 Mar;243(3):209-13.

PMID:
8936349
26.

The treatment of chronic progressive multiple sclerosis with cladribine.

Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J.

Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716-20.

27.

Cladribine in treatment of chronic progressive multiple sclerosis.

Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E.

Lancet. 1994 Jul 2;344(8914):9-13.

PMID:
7912347
28.

Marrow suppression produced by repeated doses of cladribine.

Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ.

Acta Haematol. 1994;91(1):10-5.

PMID:
8171930
29.

P300 in multiple sclerosis: a preliminary report.

Polich J, Romine JS, Sipe JC, Aung M, Dalessio DJ.

Int J Psychophysiol. 1992 Mar;12(2):155-63.

PMID:
1592668
30.

Neurology: immunotherapy in multiple sclerosis.

Sipe JC.

West J Med. 1987 Mar;146(3):351-2. No abstract available.

31.

Immunological complications in multiple sclerosis patients receiving interferon.

Rice GP, Woelfel EL, Talbot PJ, Braheny SL, Sipe JC, Knobler RL, Merigan TC, Oldstone MB.

Ann Neurol. 1985 Oct;18(4):439-42.

PMID:
2416266
32.

A neurologic rating scale (NRS) for use in multiple sclerosis.

Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB.

Neurology. 1984 Oct;34(10):1368-72.

PMID:
6541311
33.

Systemic alpha-interferon therapy of multiple sclerosis.

Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GP, Huddlestone JR, Francis GS, Hooper CK, Kamin-Lewis RM, Johnson KP, et al.

Neurology. 1984 Oct;34(10):1273-9.

PMID:
6384817
34.

Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8.

Rice GP, Finney D, Braheny SL, Knobler RL, Sipe JC, Oldstone MB.

J Neuroimmunol. 1984 Apr;6(2):75-84.

PMID:
6233298
35.

Clinical trial of natural alpha interferon in multiple sclerosis.

Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GP, Huddlestone JR, Francis GS, Hooper CJ, Kamin-Lewis RM, Johnson KP, et al.

Ann N Y Acad Sci. 1984;436:382-8. No abstract available.

PMID:
6398020
36.

The failure of monoclonal antibody-defined lymphocyte subsets to monitor disease activity in patients with multiple sclerosis.

Rice GP, Sipe JC, Braheny SL, Knobler RL, Finney DA, Oldstone MB.

Ann N Y Acad Sci. 1984;436:271-80. No abstract available.

PMID:
6241819
37.

Primary intracranial hypotension and bilateral isodense subdural hematomas.

Sipe JC, Zyroff J, Waltz TA.

Neurology. 1981 Mar;31(3):334-7.

PMID:
7193824
38.

Peripheral nerve-conduction block by high muscle-compartment pressure.

Hargens AR, Romine JS, Sipe JC, Evans KL, Mubarak SJ, Akeson WH.

J Bone Joint Surg Am. 1979 Mar;61(2):192-200. No abstract available.

PMID:
217879
39.
40.

The tegmental reticular nucleus: a cytoarchitectonic, Golgi, fluorescence histochemical and ultrastructural analysis.

Sipe JC, Riley JN, Moore RY.

Cell Tissue Res. 1978 Dec 12;194(3):463-79. No abstract available.

PMID:
365347
41.

The islands of Calleja: organization and connections.

Fallon JH, Riley JN, Sipe JC, Moore RY.

J Comp Neurol. 1978 Sep 15;181(2):375-95.

PMID:
80412
42.

Partial deficiency of muscle carnitine palmitoyltransferase with normal ketone production.

Hostetler KY, Hoppel CL, Romine JS, Sipe JC, Gross SR, Higginbottom PA.

N Engl J Med. 1978 Mar 9;298(10):553-7. No abstract available.

PMID:
272487
43.

Health: whose responsibility?

Strauss AL, Sipe JC, Knowles JH.

Science. 1978 Feb 10;199(4329):597-8. No abstract available.

PMID:
11643441
44.

Granulomatous giant cell angiitis of the central nervous system.

Sipe JC, Rosenberg JH.

West J Med. 1977 Sep;127(3):215-20. No abstract available.

45.

The lateral hypothalamic area. An ultrastructural analysis.

Sipe JC, Moore RY.

Cell Tissue Res. 1977 Apr 7;179(2):177-96.

PMID:
300656
46.
47.

Astrocytic gap junctions in the rat lateral hypothalamic area.

Sipe JC, Moore RY.

Anat Rec. 1976 Jun;185(2):247-51.

PMID:
1275310
48.

Gap junctions between human meningioma cells maintained in organ culture.

Sipe JC.

Acta Neuropathol. 1976 May 18;35(1):69-76.

PMID:
1274532
49.

Transmissible mink encephalopathy. Reduced spongiform degeneration in aged mink of the Chediak-Higashi genotype.

Marsh RF, Sipe JC, Morse SS, Hanson RP.

Lab Invest. 1976 Apr;34(4):381-6.

PMID:
131218
50.

An experimental mouse testicular teratoma as a model for neuroepithelial neoplasia and differentiation. II. Electron microscopy.

Herman MM, Sipe JC, Rubinstein LJ, Vandenberg SR, Spence AM, Vraa-Jensen J.

Am J Pathol. 1975 Nov;81(2):421-44.

Supplemental Content

Support Center